Inhalation anthrax: Dose response and risk analysis

Biosecurity and Bioterrorism

Volumn 6, Issue 2, 2008, Pages 147-159

  Coleman, Margaret E ^a   Thran, Brandolyn ^b   Morse, Stephen S ^c   Hugh Jones, Martin ^d   Massulik, Stacey ^a  

^a SYRACUSE RESEARCH CORPORATION   (United States)

^b U S ARMY CENTER FOR HEALTH PROMOTION AND PREVENTIVE MEDICINE   (United States)

^c Mailman School of Public Health ^*  (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL SPORE; EXPOSURE; HEALTH; HUMAN; MICROBIOLOGY; MORTALITY; PATHOGENICITY; REVIEW; RISK ASSESSMENT;

ANIMALS; ANTHRAX; BACILLUS ANTHRACIS; HUMANS; INHALATION EXPOSURE; RISK ASSESSMENT; SPORES, BACTERIAL; WORLD HEALTH;

ANIMALIA; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 45749152988     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2007.0066     Document Type: Review

References (68)

1. BioONE Solutions, LLC. Biological event restoration; 2004. http://proceedings.ndia.org/5460/5460/1_cavanagh.pdf. Accessed May 6, 2008.
2. Marcor Remediation, Inc. AMI Building declared anthrax-free after Marcor Remediation decontamination; 2007. http://www.marcor.com/index.cfm/do/article. display/articleid/34.
3. National Research Council. Understanding Risk. Washington, DC: National Academy Press; 1996.
4. Coleman ME, Marks HM. Mechanistic modeling of salmonellosis. Quantitative Microbiology 2000;2:227-247.
5. Coleman ME, Hope BK, Claycamp HG, Cohen JT. Microbial risk assessment scenarios, causality, and uncertainty. Microbe 2007;2(1):13-17.
6. Kaplan S, Garrick BJ. On the quantitative definition of risk. Risk Anal 1981;1(1):11-27.
7. Young GA, Zelle MR, Lincoln TE. Respiratory pathogenicity of Bacillius anthracis spores. I. Methods of study and observations of pathogenesis. J Infect Dis 1946;79:233-246.
8. Barnes JM. The development of anthrax following the administration of spores by inhalation. Br J Exper Pathol 1947;28:385-394.
9. Druett HA, Henderson DW, Packman L, Peacock A. Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores. J Hygiene 1953;51:359-371.
10. Collins MT, Replogle CR. An analysis of the respiratory infectivity of Bacillus anthracis. A1/CF-TR-1997-0078. 1997.
11. Albrink WS, Goodlow RJ. Experimental inhalation anthrax in the chimpanzee. Am J Pathol 1959;5:1055-1065.
12. Glassman HN. Industrial inhalation anthrax - discussion. Bacteriol Rev 1966;30:657-659.
13. Brachman PS, Kaufmann AF, Dalldorf FG. Industrial inhalation anthrax. Bacteriol Rev 1966;30:646-659.
14. Dahlgren CM, Buchanan LM, Decker HM, Freed SW, Phillips CR, Brachman PS. Bacillus anthracis aerosols in goat hair processing mills. Am J Hygiene 1960;72:24-31.
15. Lincoln RE, Hodges DR, Klein F, et al. Role of the lymphatics in the pathogenesis of anthrax. J Infect Dis 1965;115:481-494.
16. Cooper D. Defensive Aspects of Biological Warfare. WO 188/ 701. Washington, DC: National Archives; 1943.
17. U.S. Army. Studies on Bacillus anthracis, Part 1: Respiratory anthrax in dogs, pigs, and sheep. Report AD801504, CB-023805.01. Frederick, MD: U.S. Army Medical Unit; 1961:1-34.
18. Webb GF, Blaser MJ. Mailborne transmission of anthrax: modeling and implications. Proc Natl Acad Sci U S A 2002;99(10):7027-7032.
19. Brookmeyer R, Johnson E, Barry S. Modeling the incubation period of anthrax. Stat Med 2005;24(4):531-542.
20. Wilkening DA. Sverdlovsk revisited: modeling human inhalation anthrax. Proc Natl Acad Sci U S A 2006;103(20):7589-7594.
21. Haas CN. On the risk of mortality to primates exposed to anthrax spores. Risk Anal 2002;22(2):189-193.
22. Brachman PS. Bioterrorism: an update with a focus on anthrax. Am J Epidemiol 2002;155(11):981-987.
23. Cohen ML, Whalen T. Implications of low level human exposure to respirable B. anthracis. Applied Biosafety 2007;12(2):109-115.
24. National Research Council. Risk Assessment in the Federal Government: Managing the Process. Washington, DC: National Academy Press; 1983.
25. National Research Council. Science and Judgment. Washington, DC: National Academy Press; 1994.
26. Codex Alimentarius Commission. Principles and guidelines for the conduct of microbial risk assessment. CAC/GL-30. Geneva: World Health Organization; 1999. http://www. codexalimentarius.net/web/standard_list.do?land=en. Accessed May 7, 2008.
27. International Life Sciences Institute. Revised Framework for Microbial Risk Assessment. Washington, DC: ILSI Press; 2000.
28. Doolan DL, Freilich DA, Brice GT, et al. The US capital bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J Infect Dis 2007;195:174-184.
29. National Research Council. Reopening Public Facilities after a Biological Attack. Washington, DC: National Academy Press; 2005.
30. Marks H, Coleman M. Presenting scientific theories within risk assessments. Human and Ecological Risk Assessment 2005;11(2):271-287.
31. Hugh-Jones ME, de Vos V. Anthrax and wildlife. Rev Sci Tech Off Int Epiz 2002;21(2):359-383.
32. Opare C, Nsiire A, Awumbilla B, Akanmori BD. Human behavioural factors implicated in outbreaks of human anthrax in the Tamale municipality of northern Ghana. Acta Trop 2000;76(1):49-52.
33. Woods CW, Ospanov K, Myrzabekov A, Favorov M, Plikaytis B, Ashford DA. Risk factors for human anthrax among contacts of anthrax-infected livestock in Kazakhstan. Am J Trop Med Hyg 2004;71: 48-52.
34. Brachman PS, Plotkin SA, Bumford FH, Atchison MM. An epidemic of inhalation anthrax: the first in the twentieth century II. Epidemiology. Am J Hygiene 1960;72:6-23.
35. Brachman PS, Fekety FR. Industrial anthrax. Ann N Y Acad Sci 1958;70(3):574-584.
36. Brachman PS. Inhalation anthrax. Ann N Y Acad Sci 1980;353:83-93.
37. Grinberg LM, Abramova FA, Yampolskaya OV, Walker DH, Smith JH. Quantitative pathology of inhalational anthrax I: quantitative microscopic findings. Mod Pathol 2001;14:482-495.
38. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related inhalational anthrax-Connecticut, 2001. MMWR Morb Mortal Wkly Rep 2001c;50(47):1049-1051.
39. Brittingham KC, Ruthel G, Panchal RG, et al. Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J Immunol 2005;174:5545-5552.
40. Pickering AK, Osorio M, Lee GM, Grippe VK, Bray M, Merkel TJ. Cytokine response to infection with Bacillus anthracis spores. Infect Immunol 2004;72:6382-6389.
41. Cote CK, Rea KM, Norris SL, van Rooijen N, Welkos SL. The use of a model of in vivo macrophage depletion to study the role of macrophages during infection with Bacillus anthracis spores. Microb Pathog 2004;37:169-175.
42. Jones MB, Jani R, Ren D, Wood TK, Blaser MJ. Inhibition of Bacillus anthracis growth and virulence-gene expression by inhibitors of quorum-sensing. J Infect Dis 2005;191:1881-1888.
43. Gutting BW, Channel SR, Berger AE, et al. Mathematically modeling inhalation anthrax. Microbe 2008;3(2):78-85.
44. Gearhart JM, Hack CE, Robinson PJ, Mackie R, Andrews G, Gutting BW. A multispecies biologically-based physiological model of the kinetics and dynamics of inhaled Bacillus anthracis spores. Proceedings of the Society for Risk Analysis 2007;abstract W4-D.5:73.
45. Thran BH. Physiological models for inhalation anthrax in guinea pigs and humans. Proceedings of the Society for Risk Analysis 2007;abstract W4-D.4:141.
46. Odin M, Coleman M, McClure P, Massulik S, McGinnis P. 2007. Health Hazard Predictor (HHP) approach for microbial risk assessment. Proceedings of the Society for Risk Analysis 2007;abstract W4-D.1:116.
47. Defense Intelligence Agency. Soviet biological warfare threat. DST-161 OF-057-86; 1986.
48. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278(5):399-411.
49. Glynn JR, Bradley DJ. The relationship between infecting dose and severity of disease in reported outbreaks of salmonellosis. Epidemiol Infect 1992;109:371-388.
50. Glynn JR, Hornick RB, Levine MM, Bradley DJ. Infecting dose and severity of typhoid: analysis of volunteer data and examination of the influence of the definition of illness used. Epidemiol Infect 1995;115:23-30.
51. Mintz ED, Cartter ML, Hadler JL, Wassell JT, Zingeser JA, Tauxe RV. Dose-response effects in an outbreak of Salmonella enteritidis. Epidemiol Infect 1994;112:13-23.
52. June RC, Ferguson WW, Worfel MT. Experiments in feeding adult volunteers with Escherichia coli 55, B5, a coliform organism associated with infant diarrhea. Am J Hyg 1953:57(2):222-236.
53. Bieber D, Ramer SW, Wu CY, et al. Type IV pili, transient bacterial aggregates, and virulence of enteropathogenic Escherichia coli. Science 1998;280:2114-2118.
54. Dzhupina SI. Prognozing Epizootic Situations on the Epizootic Aspects of Siberian Ulcer. Novosibirsk: Institute of Experimental Veterinary of Siberia and Far East, Siberian Branch of the Russian Academy of Agricultural Sciences; 1996.
55. Guillemin J. Anthrax: The Investigation of a Deadly Outbreak. Berkeley, CA: University of California Press; 1999.
56. Alibek K. Biohazard. New York: Dell Publishing; 1999.
57. Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002;8(10):1019-1028.
58. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep 2001b;50(43):941-948.
59. Centers for Disease Control and Prevention. Update: investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep 2001a;50(41):889-893.
60. Jernigan DB, Stephens DS, Ashford D, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001;7:933-944.
61. Holtz TH, Ackelsberg J, Kool JL, et al. Isolated case of bioterrorism-related inhalation anthrax, New York City, 2001. Emerg Infect Dis 2003;9(6):689-696.
62. Beecher DJ. Forensic application of microbiological culture analysis to identify mail intentionally contaminated with Bacillus anthracis spores. Appl Environ Microbiol 2006;72:5304-5310.
63. Centers for Disease Control and Prevention. Anthrax Q&A: anthrax and the mail. http://www.bt.cdc.gov/agent/anthrax/faq/. Updated June 2, 2003. Accessed May 7, 2008.
64. Centers for Disease Control and Prevention. Inhalation Anthrax Associated with Dried Animal Hides - Pennsylvania and New York City. MMWR Morb Mortal Wkly Rep 2006;55(10);280-282. http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm5510a4.htm. Accessed May 7, 2008.
65. Jones MH. ANTHRAX, HUMAN, FATAL - UK (SCOTLAND). ProMed-mail Archive Number 20060816.2294; 16-AUG-2006. http://www.promedmail.org/.
66. Communicable Disease Surveillance Centre. Anthrax surveillance 1961-1980. Br Med J 1982;284:204.
67. Sandman PM. Dilemmas in emergency communications policy, 2002. www.psandman.com.
68. Sandman PM. Anthrax, bioterrorism, and risk communications: guidelines for action, 2001. www.psandman.com.